A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Elecoglipron
DRUG: Dapagliflozin
DRUG: Elecoglipron-matched placebo
DRUG: Dapagliflozin-matched placebo

Sponsor

AstraZeneca